Background: A precursor of insulin it is converted to insulin by removal of the connecting C peptide, leaving the two (A and B) chains. From every molecule of proinsulin, one molecule of insulin plus one molecule of C Peptide are produced. Preproinsulin is converted to proinsulin by the action of a signal peptidase in the lumen of the endoplasmic reticulum within pancreatic beta cells. The proinsulin is then transported from the endoplasmic reticulum to the Golgi apparatus and is further modified by the action of various enzymes to yield the ature hormone, insulin. Insulinomas exhibit many structural and immunohistochemical features in common with normal beta cells. Studies using monoclonal antibodies to proinsulin and insulin have shown proinsulin/insulin staining patterns to vary greatly among those tumours and no correlation seems to exist between the immunohistochemical staining patterns and a particular histological tumour type. A diffuse staining pattern may be observed for proinsulin which differs from the crescent-shaped perinuclear staining seen in normal beta cells suggesting abnormalities in the prohormone processing. This may be observed in about 50 per cent of insulinomas. This antibody may be used to aid in the characterisation of insulinomas or in studies of proinsulin secretion in diabetic patients with and without islet cell antibodies
Description: Rabbit polyclonal to Proinsulin
Immunogen: KLH conjugated synthetic peptide derived from Proinsulin
Specificity: ·Reacts with Human, Mouse, Rabbit and Rat.
·Isotype: IgG
Application: ·Western blotting: 1/100-500. Predicted Mol wt: 35 kDa;
·Immunohistochemistry (Frozen/paraffin tissue section): 1/100-500;
·Immunocytochemistry: 1/100-500;
·ELISA: 1/500;
·Optimal working dilutions must be determined by the end user.
